Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ocugen, Inc. - Common Stock (NQ:OCGN)

1.470 -0.010 (-0.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,725,176
Open 1.470
Bid (Size) 1.460 (900)
Ask (Size) 1.470 (1,300)
Prev. Close 1.480
Today's Range 1.440 - 1.515
52wk Range 0.6400 - 2.725
Shares Outstanding 257,328,085
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Ocugen (NASDAQ:OCGN) Beats Q1 Revenue Estimates but Widens Net Loss, Announces $115M Capital Raise to Fund Pipeline Through 2028 ↗
Via Chartmill
News headline image
Ocugen Provides Business Update with First Quarter 2026 Financial Results
From Ocugen
Via GlobeNewswire

Performance

YTD
+6.5%
+6.5%
1 Month
-17.9%
-17.9%
3 Month
+3.5%
+3.5%
6 Month
+10.5%
+10.5%
1 Year
+110.0%
+110.0%

More News

Read More
News headline image
Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes
From Ocugen
Via GlobeNewswire
Top movers in Monday's after hours session ↗
Via Chartmill
News headline image
Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes
From Ocugen
Via GlobeNewswire
Ocugen Inc (NASDAQ:OCGN) Stock Drops 7% on Q4 Revenue Miss, Highlights Clinical Pipeline ↗
Via Chartmill
News headline image
Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Present at April 2026 Investor and Industry Conferences
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire
News headline image
Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy
From Ocugen
Via GlobeNewswire
News headline image
OCGN Stock Rallies On Wall Street Optimism For Clinical Pipeline: Retail Awaits New Data ↗
Via Stocktwits
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Via Chartmill
Top movers in Wednesday's session ↗
Via Chartmill
News headline image
Ocugen (OCGN) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
Via FinancialNewsMedia
News headline image
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa
From Ocugen
Via GlobeNewswire
News headline image
Why Did OCGN Stock Rise Today? ↗
Via Stocktwits
News headline image
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
From Ocugen
Via GlobeNewswire
News headline image
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
From Ocugen
Via GlobeNewswire
News headline image
Ocugen Stock Is Surging Today: What's Driving The Action? ↗
Via Benzinga
News headline image
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
From Ocugen
Via GlobeNewswire

Frequently Asked Questions

Is Ocugen, Inc. - Common Stock publicly traded?
Yes, Ocugen, Inc. - Common Stock is publicly traded.
What exchange does Ocugen, Inc. - Common Stock trade on?
Ocugen, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ocugen, Inc. - Common Stock?
The ticker symbol for Ocugen, Inc. - Common Stock is OCGN on the Nasdaq Stock Market
What is the current price of Ocugen, Inc. - Common Stock?
The current price of Ocugen, Inc. - Common Stock is 1.470
When was Ocugen, Inc. - Common Stock last traded?
The last trade of Ocugen, Inc. - Common Stock was at 05/12/26 04:00 PM ET
What is the market capitalization of Ocugen, Inc. - Common Stock?
The market capitalization of Ocugen, Inc. - Common Stock is 378.27M
How many shares of Ocugen, Inc. - Common Stock are outstanding?
Ocugen, Inc. - Common Stock has 378M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.